Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

Small Cell ◽

Small Cell Lung ◽

First Line ◽

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s128371 ◽

2017 ◽

Vol Volume 9 ◽

pp. 505-518 ◽

Cited By ~ 7

Author(s):

Kaisa Taipale ◽

Katherine B Winfree ◽

Mark Boye ◽

Mickael Basson ◽

Ghassan Sleilaty ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Maintenance Treatment ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

PharmacoEconomics ◽

10.1007/s40273-021-01022-9 ◽

2021 ◽

Author(s):

Yong-Jin Kim ◽

Mark Oremus ◽

Helen H. Chen ◽

Thomas McFarlane ◽

Danielle Fearon ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China

Journal of Medical Economics ◽

10.1080/13696998.2019.1570221 ◽

2019 ◽

Vol 22 (4) ◽

pp. 344-349 ◽

Cited By ~ 11

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

David Hutton ◽

Qiu Li

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER

Value in Health ◽

10.1016/j.jval.2018.09.016 ◽

2018 ◽

Vol 21 ◽

pp. S3

Author(s):

M.S. Holleman ◽

M.J. Al ◽

C.A. Uyl-de Groot

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Cost-effectiveness analysis of endoscopic ultrasound as a first-line staging tool for patients with non-small-cell lung cancer

Endoscopy ◽

10.1055/s-0031-1292140 ◽

2011 ◽

Vol 43 (S 03) ◽

Author(s):

L Lai

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Endoscopic Ultrasound ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First‐Line Durvalumab in Addition to Etoposide and Platinum for Extensive‐Stage Small Cell Lung Cancer: A U.S.‐Based Cost‐Effectiveness Analysis

The Oncologist ◽

10.1002/onco.13954 ◽

2021 ◽

Author(s):

Shen Lin ◽

Shaohong Luo ◽

Dian Gu ◽

Meiyue Li ◽

Xin Rao ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

Extensive Stage

Faculty Opinions recommendation of First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736170538.793563121 ◽

2019 ◽

Author(s):

Alexandru Grigorescu

Keyword(s):

United States ◽

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis

Cancer ◽

10.1002/cncr.32368 ◽

2019 ◽

Vol 125 (20) ◽

pp. 3526-3534 ◽

Cited By ~ 18

Author(s):

XiaoMin Wan ◽

Xia Luo ◽

ChongQing Tan ◽

XiaoHui Zeng ◽

YuCong Zhang ◽

...

Keyword(s):

United States ◽

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis from A UK Healthcare Perspective

Value in Health ◽

10.1016/j.jval.2017.08.006 ◽

2017 ◽

Vol 20 (9) ◽

pp. A399 ◽

Cited By ~ 1

Author(s):

X Hu ◽

DP Goldman

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Healthcare Perspective ◽

Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand

Lung Cancer ◽

10.1016/j.lungcan.2018.04.003 ◽

2018 ◽

Vol 120 ◽

pp. 91-97 ◽

Cited By ~ 2

Author(s):

Chulaporn Limwattananon ◽

Supon Limwattananon ◽

Onanong Waleekhachonloet ◽

Thananan Rattanachotphanit

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Policy Options ◽

Small Cell Lung ◽

First Line ◽